FDA grants citizen petition on glucomannan as a dietary fiber. Effects of glucomannan supplementation on weight loss in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Mohammadpour S, Amini MR, Shahinfar H, et al. Re-evaluation of knojac gum (E 425 i) and konjac glucomannan (E 425 ii) as food additives. Mortensen A, Aguilar F, Crebelli R, et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. Keithley JK, Swanson B, Mikolaitis SL, et al. The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. Wharton S, Bonder R, Jeffery A, Christensen RAG. Long-term effects of garcinia cambogia/glucomannan on weight loss in people with obesity, PLIN4, FTO and Trp64Arg polymorphisms. Maia-Landim A, Ramirez JM, Lancho C, Poblador MS, Lancho JL. The effect of garcinia cambogia as coadjuvant in the weight loss process. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Márquez F, Babio N, Bulló M, Salas-Salvadó J. National Center for Complementary and Integrative Health. A nephrologist perspective on obesity: From kidney injury to clinical management.
Garcia-Carro C, Vergara A, Bermejo S, et al. Benefit-risk assessment of orlistat in the treatment of obesity. Effect of orlistat on plasma lipids and body weight a systematic review and meta-analysis of 33 randomized controlled trials. Sahebkar A, Simental-Mendia LE, Reiner Z, et al. What you need to know about dietary supplements.įederal Trade Commission Consumer Safety Information. Once-weekly semaglutide in adults with overweight or obesity. Wilding JPH, Batterham RL, Calanna S, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort.
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Phentermine hydrochloride.Īronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde K. Naltrexone/bupropion (Contrave) for weight loss. The current role of liraglutide in the pharmacotherapy of obesity. Liraglutide (Saxenda) as a treatment for obesity. Phentermine and topiramate extended release (Qsmia). Phentermine/topiramate (Qsmia) for chronic weight management. Clinical utility of phentermine/topiramate (Qsmia) combination for the treatment of obesity. Pharmacotherapy for obesity: What you need to know. The challenge of obesity treatment: a review of approved drugs and new therapeutic targets. doi:10.1111/ijcp.13399įrancisco Bonamichi B, Bezerra Parente E, dos Santos R, Beltzhoover R, Lee J, Nunes Salles J. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. Basagoiti-Carreno B, Sanz-Velasco A, Serrano-Moreno C, Almodovar-Ruiz F. Orlistat (marketed as Alli and Xenical) Information. Sibutramine effects on central mechanisms regulating energy homeostatis. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings.
Prescription medications to treat overweight and obesity. National Institute of Diabetes and Digestive and Kidney Diseases.
0 kommentar(er)
